APA (7th ed.) Citation

Hänggi, D., & Macdonald, R. L. (2017). Response by Hänggi and Macdonald to letter regarding article, Randomized, open-label, phase 1/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (Newton [nimodipine microparticles to enhance recovery while reducing toxicity after subarachnoid hemorrhage]). Stroke, 48(4), . https://doi.org/10.1161/STROKEAHA.117.016603

Chicago Style (17th ed.) Citation

Hänggi, Daniel, and Robert Loch Macdonald. "Response by Hänggi and Macdonald to Letter Regarding Article, Randomized, Open-label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (Newton [nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])." Stroke 48, no. 4 (2017). https://doi.org/10.1161/STROKEAHA.117.016603.

MLA (9th ed.) Citation

Hänggi, Daniel, and Robert Loch Macdonald. "Response by Hänggi and Macdonald to Letter Regarding Article, Randomized, Open-label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (Newton [nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])." Stroke, vol. 48, no. 4, 2017, https://doi.org/10.1161/STROKEAHA.117.016603.